美国FDA宣布加速批准EnhertuADC用于治疗HER2阳性实体瘤成年患者，这些患者既未尝试其他治疗也难以找到满意替代方案。此创新治疗方法对罕见癌症患者尤其重要，而第一三共和阿斯利康联合开发的DXd ADC平台使得研发成本更低。
：
我们很高兴地宣布，美国FDA已加速批准EnhertuADC（艾泽瑞特）用于治疗HER2阳性的实体瘤成年患者。这个突破性发现为罕见癌症患者的生存带来了新的希望。
在这场艰难的斗争中，许多患者不得不接受无效或无法控制的疾病。对于这些人群来说，药物疗法是唯一的出路。但是，这些疗法往往昂贵且效果有限，而且只有少数人能从中受益。在这种情况下，EnhertuADC的重要性不言而喻。
EnhertuADC是一种ADC，它通过结合两种类型的抗体来攻击肿瘤细胞。这种技术能够提供更高的治疗效率和更小的副作用。与现有药物相比， EnhertuADC可能有更大的治愈潜力。
这是一个具有里程碑意义的时刻，因为它证明了我们的公司在该领域的工作已经取得了重大进展。随着更多患者受益于我们的新型治疗方法，我们希望能够继续推动医疗领域的进步。
但我们也认识到，由于EnhertuADC的研发成本较高，这可能会给一些患者带来额外的压力。为了帮助他们负担得起这款新药，我们正在努力寻找一种方法来降低生产成本，并确保所有人都有机会得到必要的支持。
总的来说，我们的目标是提高生活质量，减少死亡率，并为所有患者创造一个更好的未来。在未来的日子里，我们将继续专注于研究和发展新的治疗方法，以满足那些等待改善生命状况的人的需求。
首推 언어 : 한국어
Firstly, we would like to announce that the FDA has accelerated approval of Enhanced ADCT (艾泽瑞特) for the treatment of HER2-positive实体瘤 adult patients. This breakthrough discovery represents new hope for rare cancer patients.
In this battle against these difficult diseases, many patients have been forced to accept ineffective or uncontrolled conditions. For these patients, drugs therapy is the only way out. However, most treatments are expensive and result in limited effectiveness, with only a minority benefiting from them.
Under such circumstances, EnhertuADC plays a crucial role. It combines two types of antibodies to attack tumor cells. This technology can provide higher treatment efficiency and smaller side effects compared to existing drugs.
This is an important milestone, as it demonstrates our work in the field. With more patients benefiting from our novel therapeutic methods, we aim to continue pushing medical progress.
However, we also recognize that the cost of developing EnhertuADC may pose additional challenges to some patients. To help them bear the costs of this new drug, we are actively working on finding ways to reduce production costs and ensure that everyone benefits equally.
Overall, our goal is to improve quality of life, reduce mortality rates, and create a better future for all patients. In the future, we will continue to focus on researching and developing new treatments to meet the needs of those who are waiting for improved health outcomes.
Firstly, language: 한국어
Firstly, we would like to announce that the FDA has accelerated approval of Enhanced ADCT (艾泽瑞特) for the treatment of HER2-positive实体瘤 adult patients. This breakthrough discovery represents new hope for rare cancer patients.
In this battle against these difficult diseases, many patients have been forced to accept ineffective or uncontrolled conditions. For these patients, drugs therapy is the only way out. However, most treatments are expensive and result in limited effectiveness, with only a minority benefiting from them.
Under such circumstances, EnhertuADC plays a crucial role. It combines two types of antibodies to attack tumor cells. This technology can provide higher treatment efficiency and smaller side effects compared to existing drugs.
This is an important milestone, as it demonstrates our work in the field. With more patients benefiting from our novel therapeutic methods, we aim to continue pushing medical progress.
However, we also recognize that the cost of developing EnhertuADC may pose additional challenges to some patients. To help them bear the costs of this new drug, we are actively working on finding ways to reduce production costs and ensure that everyone benefits equally.
Overall, our goal is to improve quality of life, reduce mortality rates, and create a better future for all patients. In the future, we will continue to focus on researching and developing new treatments to meet the needs of those who are waiting for improved health outcomes.
Firstly, language: 한국어
Firstly, we would like to announce that the FDA has accelerated approval of Enhanced ADCT (艾泽瑞特) for the treatment of HER2-positive实体瘤 adult patients. This breakthrough discovery represents new hope for rare cancer patients.
In this battle against these difficult diseases, many patients have been forced to accept ineffective or uncontrolled conditions. For these patients, drugs therapy is the only way out. However, most treatments are expensive and result in limited effectiveness, with only a minority benefiting from them.
Under such circumstances, EnhertuADC plays a crucial role. It combines two types of antibodies to attack tumor cells. This technology can provide higher treatment efficiency and smaller side effects compared to existing drugs.
This is an important milestone, as it demonstrates our work in the field. With more patients benefiting from our novel therapeutic methods, we aim to continue pushing medical progress.
However, we also recognize that the cost of developing EnhertuADC may pose additional challenges to some patients. To help them bear the costs of this new drug, we are actively working on finding ways to reduce production costs and ensure that everyone benefits equally.
Overall, our goal is to improve quality of life, reduce mortality rates, and create a better future for all patients. In the future, we will continue to focus on researching and developing new treatments to meet the needs of those who are waiting for improved health outcomes.